Sabrina Kay
Sabrina Kay's purchase track record
Sabrina Kay has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/9/2023 | EWBC | $300K | +34.2% | +29.9% | +6.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Hagerty releases Q2 2026 earnings call transcript. Hagerty Inc. has published the full transcript of its second-quarter 2026 earnings call, providing investors with detailed insights into the company's recent performance. This release follows the stock trading near its 52-week high, reflecting current market interest in the company's financial updates.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
MannKind Presents Furoscix Data at HFSA 2026. MannKind reported new data at the HFSA 2026 conference showing that its Furoscix ReadyFlow autoinjector produced urine output comparable to IV furosemide. The study supports the use of the device for managing edema in patients with heart failure and chronic kidney disease. Truist Securities maintained its rating on the stock but lowered its price target to $5.
Transaction History
| EWBC | ▲ Buy | Grant | 1,156 | $0 | 5/18/2026 | View on chart |
| HGTY | ▲ Buy | Grant | 11,871 | $0 | 4/1/2026 | View on chart |
| EWBC | ▲ Buy | Grant | 1,417 | $0 | 5/20/2025 | View on chart |
| HGTY | ▲ Buy | Grant | 13,828 | $0 | 4/1/2025 | View on chart |
| EWBC | ▲ Buy | Grant | 1,818 | $0 | 5/28/2024 | View on chart |
| HGTY | ▲ Buy | Grant | 9,836 | $0 | 4/1/2024 | View on chart |
| MNKD | ▲ Buy | Grant | 107,033 | $350K | 2/4/2024 | View on chart |
| EWBC | ▲ Buy | Grant | 2,603 | $0 | 5/24/2023 | View on chart |
| EWBC | ▲ Buy | Open Market | 6,840 | $300K | 5/9/2023 | View on chart |
| HGTY | ▲ Buy | Grant | 10,297 | $0 | 4/1/2023 | View on chart |
| EWBC | ▲ Buy | Grant | 2,006 | $0 | 6/30/2022 | View on chart |
| HGTY | ▲ Buy | Grant | 8,341 | $0 | 4/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Cantor Fitzgerald Lowers EWBC Price Target to $146
Cantor Fitzgerald maintained an Overweight rating on East West Bancorp but reduced its price target to $146. The stock is set to report earnings next week, with Wall Street generally expecting growth in key metrics. While the average analyst target remains near $150, this specific adjustment reflects a more cautious outlook on the bank's near-term performance.
Cantor Fitzgerald Lowers EWBC Price Target to $146. Cantor Fitzgerald maintained an Overweight rating on East West Bancorp but reduced its price target to $146. The stock is set to report earnings next week, with Wall Street generally expecting growth in key metrics. While the average analyst target remains near $150, this specific adjustment reflects a more cautious outlook on the bank's near-term performance.